Interaction of SSR161421, a novel specific adenosine A3 receptor antagonist with adenosine A3 receptor agonists both in vitro and in vivo

被引:2
作者
Mikus, Endre G. [1 ]
Boer, Kinga [1 ]
Timari, Geza [1 ]
Urban-Szabo, Katalin [1 ]
Kapui, Zoltan [1 ]
Szeredi, Judit [1 ]
Gerber, Katalin [1 ]
Szabo, Tibor [1 ]
Batori, Sandor [1 ]
Finet, Michel [1 ]
Aranyi, Peter [1 ]
Galzin, Anne-Marie [1 ]
机构
[1] Sanofi Co Ltd, H-1045 Budapest, Hungary
关键词
Human adenosine A(3) receptors; Adenosine A(3) receptor antagonist; Ear oedema; Histamine release; FUNCTIONAL-CHARACTERIZATION; RELEASE;
D O I
10.1016/j.ejphar.2012.11.046
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel adenosine A(3) receptor antagonist (SSR161421) was characterized by both receptor binding assays and pharmacological tests. Binding studies on cloned human adenosine receptors showed that SSR161421 has high affinity for adenosine hA(3) receptors (K-i = 0.37 nM) with at least 1000-fold selectivity compared to hA(1), hA(2A) and hA(2B) receptors. The receptor antagonist nature of SSR161421 was determined in a functional study on Chinese hamster ovarian cells (CHO) cells expressing human adenosine A(3) receptors. SSR161421 competitively antagonized the effect of 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide (CI-IB-MECA) on cAMP production with a pA2 value in a luciferase reporter gene construct. In mice, intravenously administered SSR161421 inhibited the N6-(4-aminobenzyl)-adenosine-5'-N-methyl-uronamide dihydrochloride (AB-MECA) induced increase in plasma histamine levels (ED50=2.0 mg/kg) and the CI-IB-MECA evoked plasma extravasation (ID50=2.9 mg/kg) and oedema formation (ID50=4.6 mg/kg) in mouse ear. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 16 条
[1]  
BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087
[2]  
BRACKETT LE, 1994, BIOCHEM PHARMACOL, V47, P801
[3]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[4]   STUDIES ON THE RECEPTOR MEDIATING CYCLIC AMP-INDEPENDENT ENHANCEMENT BY ADENOSINE OF IGE-DEPENDENT MEDIATOR RELEASE FROM RAT MAST-CELLS [J].
CHURCH, MK ;
HUGHES, PJ ;
VARDEY, CJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (01) :233-242
[5]   INHALED ADENOSINE AND GUANOSINE ON AIRWAY-RESISTANCE IN NORMAL AND ASTHMATIC SUBJECTS [J].
CUSHLEY, MJ ;
TATTERSFIELD, AE ;
HOLGATE, ST .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (02) :161-165
[6]   ADENOSINE IN BRONCHOALVEOLAR LAVAGE FLUID IN ASTHMA [J].
DRIVER, AG ;
KUKOLY, CA ;
ALI, S ;
MUSTAFA, SJ .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (01) :91-97
[7]   Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release [J].
Ezeamuzie, CI ;
Philips, E .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (01) :188-194
[8]  
Feoktistov I, 1996, DRUG DEVELOP RES, V39, P333, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<333::AID-DDR14>3.0.CO
[9]  
2-2
[10]   Disparity in FcεRI-Induced Degranulation of Primary Human Lung and Skin Mast Cells Exposed to Adenosine [J].
Gomez, Gregorio ;
Zhao, Wei ;
Schwartz, Lawrence B. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (03) :479-487